Skip to main content

Table 1 Patient Demographic Data A total of 54 metastatic breast cancer patients were recruited for this study

From: CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome

   (n = 54)
Age (median)   57 years
Gender Female 54 (100%)
Race Asian 4 (7%)
  Black 4 (7%)
  Hispanic 1 (2%)
  White 33 (61%)
  Other/unknown 12 (22%)
Grade 0 1 (2%)
  1 1 (2%)
  2 14 (26%)
  3 21 (39%)
  Unknown 17 (31%)
Histology IDC* 48 (76%)
  ILC 3 (5%)
  Unknown 12 (19%)
Estrogen receptor Positive( +) 22 (41%)
  Negative (−) 27 (50%)
  Unknown 5 (9%)
Progesterone receptor Positive ( +) 13 (24%)
  Negative (-) 37 (69%)
  Unknown 4 (7%)
HER2 receptor Positive ( +) 11 (20%)
  Negative (−) 40 (74%)
  Unknown 3 (6%)
TNBC   20 (37%)
CAMLs present   53 (98%)
Average CAMLs per patient 5 CAMLs  
CTCs present   34 (63%)
Average CTCs per patient   4 CTCs
Average prior therapies   3
  1. Number of average prior therapies was calculated using patients with a confirmed number of prior therapies. *9 IDC patients were of the IBC subtype